Interferons induced early after SARS-CoV-2 infection are crucial for shaping immunity and preventing severe COVID-19. We previously demonstrated that injection of pegylated interferon-lambda accelerated viral clearance in COVID-19 patients (NCT04354259). To determine if the viral decline is mediated by enhanced immunity, we assess in vivo responses to interferon-lambda by single cell RNA sequencing and measure SARS-CoV-2-specific T cell and antibody responses between placebo and interferon-lambda-treated patients. Here we show that interferon-lambda treatment induces interferon stimulated genes in peripheral immune cells expressing IFNLR1, including plasmacytoid dendritic cells and B cells. Interferon-lambda does not affect SARS-CoV-2-specific antibody levels or the magnitude of virus-specific T cells. However, we identify delayed T cell responses in older adults, suggesting that interferon-lambda can overcome delays in adaptive immunity to accelerate viral clearance in high-risk patients. Altogether, interferon-lambda offers an early COVID-19 treatment option for outpatients to boost innate antiviral defenses without dampening peripheral adaptive immunity.
Dried blood spots (DBS) are commonly used for serologic testing for viruses and provide an alternative collection method when phlebotomy and/or conventional laboratory testing are not readily available. DBS collection could be used to facilitate widespread testing for SARS-CoV-2 antibodies to document past infection, vaccination, and potentially immunity. We investigated the characteristics of Roche’s Anti-SARS-CoV-2 (S) assay, a quantitative commercial assay for antibodies against the spike glycoprotein. Antibody levels were reduced relative to plasma following elution from DBS. Quantitative results from DBS samples were highly correlated with values from plasma (r2 = 0.98), allowing for extrapolation using DBS results to accurately estimate plasma antibody levels. High concordance between plasma and fingerpick DBS was observed in PCR-confirmed COVID-19 patients tested 90 days or more after the diagnosis (45/46 matched; 1/46 mismatched plasma vs. DBS). The assessment of antibody responses to SARS-CoV-2 using DBS may be feasible using a quantitative anti-S assay, although false negatives may rarely occur in those with very low antibody levels.
Lymphodepletion chemotherapy followed by CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell infusion is a novel treatment for refractory B cell malignancies. Infectious complications of CD19 CAR-T cell immunotherapy have not been studied. We described infections between 0–28 and 29–90 days after CD19 CAR-T cell infusion in patients with relapsed and/or refractory CD19+ malignancies treated in a phase 1/2 open-label trial (NCT01865617). We used Poisson and Cox regression to evaluate pre- and post-CAR-T cell infusion risk factors for infection, respectively. Patients receiving anti-tumor therapy after CAR-T cell infusion were censored. The cohort included 133 patients with acute lymphoblastic leukemia (ALL, n = 47), chronic lymphocytic leukemia (CLL, n = 24), and non-Hodgkin lymphoma (NHL, n = 62). There were 43 infections in 30 patients (22.6%) within 28 days after CAR-T cell infusion with a mean of 1.19 infections per 100 days-at-risk (Fig 1). Among 119 patients followed at our center from day 29–90, there were a mean of 0.67 infections per 100 days-at-risk. Six patients (4.5%) developed invasive fungal infections. Infection was a primary or secondary cause of death in 2 patients (1.5%). Pre-CAR-T cell infusion factors that were associated with more infections included a diagnosis of ALL, >=4 prior chemotherapeutic regimens, and highest CAR-T cell dose (2 × 107 cells/kg) (p values 3-fold increased hazard for infection (P < 0.001) and was the primary risk factor. Patients receiving an optimized lymphodepletion and CAR-T cell dose regimen had a mean of 0.74 and 0.63 infections per 100 days-at-risk between days 0–28 and 29–90 with no fatal infections. The incidence of infectious complications after CD19 CAR-T cell immunotherapy was similar to that seen in patients with relapsed and/or refractory B cell malignancies receiving salvage chemoimmunotherapies. Patients with more prior chemotherapy regimens and severe CRS after CAR-T cell infusion had the highest risk for infection. Fatal infections were rare, and patients receiving optimized regimens had fewer infectious complications. D. Li, Juno Therapeutics: Employee and Shareholder, Salary; S. Riddell, Juno Therapeutics: Consultant, Grant Investigator and Shareholder, Research support; D. Maloney, Juno Therapeutics: Grant Investigator, Research support; C. Turtle, Juno Therapeutics: Investigator, Research support
Interferons (IFNs) are antiviral cytokines induced very early after SARS-CoV-2 infection and are crucial for viral clearance, shaping immunity, and preventing the development of severe COVID-19. We previously demonstrated that a single injection of peginterferon-lambda1 (PEG-IFN-λ) accelerated viral clearance in COVID-19 patients. To determine if the rapid viral decline was mediated by enhanced immunity, we assessed in vivo responses to PEG-IFN-λ by single cell RNA sequencing and measured SARS-CoV-2-specific T cell and antibody responses between placebo and PEG-IFN-λ-treated patients. PEG-IFN-λ treatment induced interferon stimulated genes in peripheral immune cells expressing IFNLR1 , with plasmacytoid dendritic cells having the greatest response, followed by B cells. PEG-IFN-λ did not significantly affect SARS-CoV-2-specific antibody levels in plasma or the magnitude or functionality of virus-specific T cells. However, we identified a delayed T cell response in older adults, suggesting that PEG-IFN-λ can overcome the delay in adaptive immunity to accelerate viral clearance in patients most at risk for severe disease. Taken together, PEG-IFN-λ offers an early COVID-19 treatment option for outpatients to boost innate antiviral defenses without dampening peripheral SARS-CoV-2 adaptive immunity